How LUTATHERA May Help

Clinical Trial Results for LUTATHERA

In a clinical trial, 229 people with midgut NETs who received LUTATHERA in combination with 30 mg of long-acting octreotide were compared with those who received 60 mg of long-acting octreotide alone.

Longer Progression-Free Survival (PFS) for Patients Treated With LUTATHERA

In the LUTATHERA group, the relative risk of the cancer getting worse or death was reduced by 79% compared with people treated with 60 mg of long-acting octreotide alone.
79%
 

 

More people treated with LUTATHERA had their tumors shrink compared with people treated with 60 mg of long-acting octreotide alone

13% of people
in the LUTATHERA with 30 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
12% (14 of 116 people)

Complete response (tumors disappear)b:
1% (1 of 116 people)

4% of people
in the 60 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
4% (4 of 113 people)

Complete response (tumors disappear)b:
0% (0 of 113 people)

aTumors shrink to ≥30% from baseline.

bTumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.

Talk to your health care professional to see if LUTATHERA is right for you in your treatment journey.